Novartis Campus Updates: New ASC4FIRST Clinical Trial Results for Scemblix in Basel
Long-term clinical findings for the chronic myeloid leukemia treatment Scemblix® (asciminib) were unveiled from the ASC4FIRST trial (NCT04971226) at the American Society of Clinical Oncology Annual Meeting. Released from Novartis, these 144-week results offer deeper insight into the treatment's sustained efficacy, safety profile, and tolerability for newly diagnosed patients.
Evaluating Long-Term Efficacy in Chronic Myeloid Leukemia
The trial compared Scemblix against standard-of-care tyrosine kinase inhibitors (TKIs), including imatinib and second-generation options. Over the 144-week period, the data demonstrated an increasingly wider margin of major molecular response rates favoring Scemblix over standard alternatives. Specifically, patients receiving Scemblix sustained higher rates of retention on therapy and achieved deeper molecular responses, underlining its potential for long-term disease management.
Safety and Patient Tolerability Insights
Managing a lifelong condition like chronic myeloid leukemia requires balancing effective disease control with daily life quality. The extended follow-up data indicated that Scemblix maintained a favorable safety profile consistent with previous evaluations, showing fewer grade 3 or higher adverse events and lower discontinuation rates compared to imatinib and second-generation TKIs.
To explore more architectural landmarks, scientific milestones, and cultural points of interest across the city, discover local highlights with Musemap (musemap.art). You can also browse museums or search for specific local destinations using the search tool.
